Merck ditches vibostolimab and favezelimab following huge pivotal programmes.

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.

The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.

Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.

Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.

But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

Meanwhile, the RayzeBio-originated RYZ101 is back in Action.